[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-atrophic-gastritis-cag\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-atrophic-gastritis-cag":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100612186","correlation-study-of-atrophic-gastritis-and-dyspepsia-symptoms-100612186",false,"NCT07250308","Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms","A Prospective Observational Study on the Correlation Between Pathologically Confirmed Chronic Atrophic Gastritis and Functional Dyspepsia Symptoms","Inclusion Criteria:\n\n1. Age 18-75 years\n2. Recent gastroscopic examination (within 1 year) suggesting chronic atrophic gastritis\n3. Underwent standardized pathological examination (5-point gastric mucosa biopsy according to the \"Updated Sydney System\" including antrum, body, and angle)\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. Gastric cancer or suspected malignant lesions\n2. Concomitant significant other gastrointestinal diseases (e.g., ulcer, Barrett's esophagus, etc.)\n3. Autoimmune gastritis\n4. Unable to complete questionnaire survey",true,"ALL","18 Years","75 Years",{"count":21,"type":22},315,"ESTIMATED","1 Day","OBSERVATIONAL","Background:\n\nDyspepsia is a common gastrointestinal complaint globally, affecting approximately 21.8% of the population. Among patients presenting with dyspeptic symptoms, over 80% are diagnosed with functional dyspepsia (FD), while approximately 16% are found to have chronic atrophic gastritis (CAG). CAG represents an important precancerous condition in the gastric cancer cascade, yet the relationship between pathologically confirmed CAG and dyspeptic symptoms remains poorly understood. The significant symptom overlap between CAG and FD creates diagnostic challenges in clinical practice.\n\nStudy Objectives:\n\nThe primary objective is to determine whether there are significant differences in the prevalence and severity of dyspeptic symptoms (including epigastric pain, burning sensation, early satiety, and postprandial fullness) between patients with pathologically confirmed CAG and those without CAG (non-CAG group) among individuals who present with endoscopic features suggestive of atrophic gastritis.\n\nSecondary objectives include: (1) analyzing the independent effects of various covariates (Helicobacter pylori infection, dietary habits, sleep quality, psychological factors) on dyspeptic symptoms; (2) developing a symptom-based predictive model for pathological CAG; and (3) conducting exploratory serum metabolomics analysis to identify potential biomarkers and metabolic pathways associated with FD symptoms.\n\nStudy Design:\n\nThis is a single-center, prospective, observational study conducted at the Third Affiliated Hospital of Zhejiang Chinese Medical University. The study will enroll approximately 258-315 adult patients (aged 18-75 years) who undergo endoscopy showing features suggestive of CAG within the past year. All participants will undergo standardized 5-point gastric mucosal biopsy according to the Updated Sydney System. Based on histopathological results, patients will be classified into pathological CAG group (presence of gastric mucosal atrophy) or non-CAG group (absence of atrophy). The study aims to recruit at least 80 pathologically confirmed non-CAG patients for comparison.\n\nStudy Procedures:\n\nAfter obtaining informed consent, all enrolled patients will complete a comprehensive assessment at baseline including: demographic information, medical history, endoscopy and pathology results, Gastrointestinal Symptom Scale (GOSS) questionnaire using a 7-point Likert scale, H. pylori infection status (serology), dietary habits assessment, Pittsburgh Sleep Quality Index (PSQI), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), and perceived stress evaluation. A subset of participants will provide fasting blood samples for non-targeted metabolomics analysis using liquid chromatography-mass spectrometry (LC-MS) to identify metabolites related to amino acids, organic acids, lipids, and neurotransmitter precursors. This is a non-interventional study with all data and sample collection completed at enrollment without long-term follow-up.\n\nPrimary Outcome:\n\nThe primary outcome is the difference between pathological CAG and non-CAG groups in the prevalence and severity of dyspeptic symptoms, particularly cardinal FD symptoms (epigastric pain, burning, early satiety, postprandial fullness), assessed using the GOSS scale. A symptom score ≥4 on any cardinal symptom will define the presence of clinically significant FD symptoms.\n\nExpected Duration:\n\nThe study is expected to last 24 months, including preparation, patient recruitment with data collection, and final statistical analysis and reporting phases.\n\nSignificance:\n\nThis study will provide evidence-based insights into the relationship between pathologically confirmed CAG and dyspeptic symptoms, potentially improving symptom management strategies and patient counseling. The metabolomics component may reveal novel biomarkers and pathways underlying symptom generation, laying groundwork for future mechanistic studies and personalized therapeutic approaches. Results will inform clinical practice and serve as preliminary data for larger-scale investigations.",[27,28],"Functional Dyspepsia","Chronic Atrophic Gastritis (CAG)",[30,31],"Serumomics","symptom","RECRUITING","2025-11-24",{"date":35,"type":36},"2025-11-26","ACTUAL",{"date":38,"type":36},"2025-10-01",{"date":40,"type":22},"2026-08-31",{"name":42,"class":43},"The Third Affiliated hospital of Zhejiang Chinese Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":44},"100586192","association-of-sleep-quality-with-pathologic-staging-acupuncture-treatment-in-patients-with-chronic-atrophic-gastritis-a-cross-sectional-study-100586192","NCT06912178","Association of Sleep Quality With Pathologic Staging, Acupuncture Treatment in Patients With Chronic Atrophic Gastritis: a Cross-sectional Study","Inclusion Criteria:\n\n1. Have been diagnosed with chronic atrophic gastritis;\n2. Be between the ages of 18 and 75, with no restrictions on gender;\n3. Read the informed consent form, sign it, and consent to participate in this study.\n\nExclusion Criteria:\n\n1. autoimmune gastritis (chronic atrophic gastritis type A);\n2. patients with gastroesophageal reflux disease (GERD) as determined by endoscopy or other examinations, or patients with high-grade intraepithelial neoplasia pathologically as determined by upper gastrointestinal endoscopy and gastric mucosal biopsy;\n3. patients with confirmed or unexcluded malignant tumors, particularly esophageal and gastric cancer;patients with other upper gastrointestinal pathologies, such as Barrett's esophagus or peptic ulcer;\n4. additional physical, mental, psychological, or pathological conditions that may impact sleep scores, such as the use of medications for insomnia, night shifts, jet lag, major events, severe neurosis, menopausal syndrome, uncontrolled hyperthyroidism, severe diabetic peripheral neuropathy, within a month after surgical trauma, etc.\n5. People who use medicines that can make you sleepy at the same time and stop using them for less than a month;\n6. People who can't finish the questionnaire because they're unconscious, can't talk regularly, or have other issues; people who don't have enough information.",{"count":52,"type":22},120,"In order to inform clinical treatment decisions and maximize treatment outcomes, this observational study set out to examine the relationship between pathological severity and sleep quality in patients with CAG. The idea that \"if the stomach is not in harmony, you will be restless\" is supported by this evidence from traditional Chinese medicine. Assessing patients' knowledge and acceptance of acupuncture therapy, determining the current general trend in CAG treatment, and assessing the initial effectiveness of acupuncture therapy in treating CAG with sleep disturbances. It is envisaged that the aforementioned investigations will aid in further refining the clinical research strategy of acupuncture and moxibustion with CAG with sleep disorders, enhance the effectiveness of treatment, and offer a more cost-effective and practical choice for treating CAG with sleep disorders.\n\nThe primary research issue is: can the traditional Chinese medical notion of \"restlessness due to disharmony of the stomach\" be validated in order to ascertain whether there is a correlation between pathological severity and sleep quality in patients with chronic atrophic gastritis? The pathological conditions of CAG patients were gathered based on the most recent gastroscopy report within a year, and the patients' sleep quality scores from the previous month were gathered via a questionnaire.",[28],[56],"chronic atrophic gastritis; sleep quality; OLGA; OLGIM; pathologic; acupuncture; cross-sectional","NOT_YET_RECRUITING","2025-03-29",{"date":60,"type":36},"2025-04-04",{"date":62,"type":22},"2025-03-30",{"date":64,"type":22},"2026-03-30",{"name":66,"class":43},"Yi Liang",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":44},"100570473","correlation-among-various-olga-and-olgim-stages-digestive-symptom-scores-and-acupuncture-treatment-in-patients-with-chronic-atrophic-gastritis-100570473","NCT06707701","Correlation Among Various OLGA and OLGIM Stages, Digestive Symptom Scores, and Acupuncture Treatment in Patients with Chronic Atrophic Gastritis","Correlation Among Various OLGA and OLGIM Stages, Digestive Symptom Scores, and Acupuncture Treatment in Patients with Chronic Atrophic Gastritis:a Multicenter Cross-sectional Pilot Survey","Inclusion Criteria:\n\n* Fulfill the diagnostic criteria for chronic atrophic gastritis;\n* Individuals aged 18 to 75 years, irrespective of gender;\n* Capable of comprehending and consenting to participate in this study by signing the informed consent form.\n\nExclusion Criteria:\n\n* Autoimmune gastritis (type A chronic atrophic gastritis);\n* Patients diagnosed with Gastroesophageal Reflux Disease (GERD) by endoscopy or other examinations or patients diagnosed with high-grade intraepithelial neoplasia by upper gastrointestinal endoscopy and gastric mucosal biopsy pathology;\n* Patients with confirmed or unable to exclude malignant tumors, especially esophageal and gastric cancers; patients with other upper gastrointestinal tract pathologies such as peptic ulcer or Barrett's esophagus;\n* Those who cannot complete the questionnaire due to unconsciousness, inability to communicate normally or other reasons; those with incomplete information.",{"count":75,"type":22},400,"Brief Summary Template for the Study:\n\nThe goal of this observational study is to examine the relationship between digestive symptom scores, serum pepsinogen indices, and histopathological OLGA and OLGIM systematic staging of the gastric mucosa in patients with chronic atrophic gastritis(CAG), aiming to determine the degree of correlation between clinical manifestations, non-invasive laboratory tests, and the gold standard of diagnostic histopathology.To evaluate the comprehensive therapy, readiness and acceptance of acupuncture, utilization rates of various acupuncture therapies, self-assessed efficacy of acupuncture, and endoscopic histopathological alterations in patients with CAG.According to the aforementioned study, it is anticipated to enhance the optimization of acupuncture clinical research protocols for chronic atrophic gastritis, improve treatment efficacy, and offer more effective and rational therapy alternatives for patients.The main question it aims to answer is:\n\nTo determine if the outcomes of combined serologic testing of symptoms in patients with CAG can serve as a method for monitoring disease development and if long-term follow-up can be supported？\n\nA group of participants with recorded GI symptom scores and blood pepsinogen levels will respond to online survey questions regarding the severity of their chronic atrophic gastritis progression over the course of 1 year.",[28],[79,80,81,82,83],"chronic atrophic gastritis","global overall symptom scale","serum pepsinogen","operative link for gastritis assessment","operative link for gastric intestinal metaplasia assessment","2024-11-27",{"date":86,"type":36},"2024-12-02",{"date":88,"type":22},"2024-12-30",{"date":90,"type":22},"2025-12-30",{"name":66,"class":43}]